

# C6 vs Pathway Expression

C6		IC( $\Delta$ )	P-val	FDR
BRAF		0.746(0.008)	2.62e-06	1.50e-05
TAUBE_EMT		0.706(0.009)	2.62e-06	1.50e-05
GROGER_EMT		0.702(0.009)	2.62e-06	1.50e-05
GU_PDEF_TARGETS		0.702(0.009)	2.62e-06	1.50e-05
P53_DN.V1_DN		0.700(0.011)	2.62e-06	1.50e-05
ROY_WOUND_BLOOD_VESSEL		0.692(0.009)	2.62e-06	1.50e-05
ETV1_UP		0.692(0.013)	2.62e-06	1.50e-05
JAEGER_METASTASIS		0.687(0.008)	2.62e-06	1.50e-05
COLDREN_GEFITINIB_RESISTANCE		0.686(0.009)	2.62e-06	1.50e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL		0.683(0.009)	2.62e-06	1.50e-05
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3		0.681(0.008)	2.62e-06	1.50e-05
SENGUPTA_NASOPHARYNGEAL_CARCINOMA		0.679(0.008)	2.62e-06	1.50e-05
ONDER_CDH1_TARGETS_2		0.679(0.009)	2.62e-06	1.50e-05
SMID_BREAST_CANCER_NORMAL_LIKE		0.677(0.009)	2.62e-06	1.50e-05
PIGMENT_METABOLIC_PROCESS		0.672(0.013)	2.62e-06	1.50e-05
PIGMENT_BIOSYNTHETIC_PROCESS		0.672(0.014)	2.62e-06	1.50e-05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE		0.671(0.008)	2.62e-06	1.50e-05
KASLER_HDAC7_TARGETS_1_UP		0.653(0.014)	2.62e-06	1.50e-05
HINATA_NFKB_TARGETS_KERATINOCYTE		0.651(0.008)	2.62e-06	1.50e-05
LEIN_OLIGODENDROCYTE_MARKERS		0.650(0.017)	2.62e-06	1.50e-05
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN		-0.668(0.010)	2.62e-06	2.21e-05
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION		-0.668(0.012)	2.62e-06	2.21e-05
HALLMARK_ESTROGEN_RESPONSE_LATE		-0.669(0.010)	2.62e-06	2.21e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP		-0.670(0.010)	2.62e-06	2.21e-05
LIM_MAMMARY_STEM_CELL_DN		-0.677(0.009)	2.62e-06	2.21e-05
JAEGER_METASTASIS_DN		-0.678(0.009)	2.62e-06	2.21e-05
LANDIS_BREAST_CANCER_PROGRESSION_UP		-0.678(0.009)	2.62e-06	2.21e-05
LANDIS_BREAST_CANCER_PROGRESSION		-0.689(0.007)	2.62e-06	2.21e-05
BOYALT_LIVER_CANCER_SUBCLASS_G1_UP		-0.689(0.008)	2.62e-06	2.21e-05
TAUBE_EMT_DN		-0.693(0.009)	2.62e-06	2.21e-05
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN		-0.693(0.008)	2.62e-06	2.21e-05
SMID_BREAST_CANCER_NORMAL_LIKE_DN		-0.694(0.011)	2.62e-06	2.21e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL		-0.695(0.008)	2.62e-06	2.21e-05
COLDREN_GEFITINIB_RESISTANCE_DN		-0.705(0.009)	2.62e-06	2.21e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP		-0.710(0.008)	2.62e-06	2.21e-05
GROGER_EMT_DN		-0.711(0.009)	2.62e-06	2.21e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP		-0.719(0.009)	2.62e-06	2.21e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN		-0.729(0.008)	2.62e-06	2.21e-05
AIGNER_ZEB1_TARGETS		-0.744(0.008)	2.62e-06	2.21e-05
P53_DN.V1		-0.761(0.009)	2.62e-06	2.21e-05